Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Follow-Up Questions
¿Cuál es el ratio P/E de Incyte Corp (INCY)?
El ratio P/E de Incyte Corp es 508.682
¿Quién es el CEO de Incyte Corp?
Mr. Bill Meury es el President de Incyte Corp, se unió a la empresa desde 2025.
¿Qué tal es el rendimiento del precio de la acción INCY?
El precio actual de INCY es de $104.01, ha increased un 2.4% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Incyte Corp?
Incyte Corp pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Incyte Corp?
La capitalización bursátil actual de Incyte Corp es $20.3B
¿Es Incyte Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 24 analistas han realizado calificaciones de análisis para Incyte Corp, incluyendo 10 fuerte compra, 8 compra, 15 mantener, 1 venta, y 10 fuerte venta
